ATRN-333 / Aprea - LARVOL DELTA

Convection enhanced delivery of a novel ATR inhibitor synergizes with systemic lomustine for improved treatment of glioblastoma (AACR 2024) - "Here, we employ a combination approach using a next-generation macrocyclic ATR inhibitor, ATRN-333, to sensitize GBM tumors to alkylators. Our results demonstrate that ATR inhibitor/lomustine combination therapy, used in conjunction with a CED platform, is a powerful avenue for GBM treatment and a viable option for potential clinical implementation. Note: AJ and TL contributed equally to this work."

Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024 (GlobeNewswire) - "Abstract Number: 7117: This poster describes a combination approach using a next-generation macrocyclic ATR inhibitor, ATRN-333, to sensitize glioblastoma (GBM) tumors to lomustine, an oral DNA alkylating agent....There was a clear synergistic effect between lomustine and ATRN-333 in GBM cell lines. ATRN-333 effectively sensitized both flank and intracranial tumors to lomustine in vivo. When administered via CED, ATRN-333 showed favorable intracranial retention and was well tolerated in mice when combined with lomustine."

Preclinical • Glioblastoma